Amarin Corporation PLC (AMRN) to Ring The NASDAQ Stock Market Closing Bell

ADVISORY, Nov. 1, 2011 (GLOBE NEWSWIRE) --

What:

Amarin Corporation PLC (AMRN), a prominent biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease, will visit the NASDAQ MarketSite in New York City's Times Square in recognition of its recent progress and listing on the NASDAQ Global Market.

In honor of the occasion, Joseph S. Zakrzewski, CEO, will officially ring The NASDAQ Stock Market Closing Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Wednesday, November 2nd, 2011 – 3:45 p.m. to 4:00 p.m. ET   

Contact:

Stephen Schultz

Senior Director, Investor Relations and Communications

(860) 572-4979 x292

Stephen.schultz@amarincorp.com

NASDAQ MarketSite:

Jen Knapp

(212) 401-8916

Jennifer.knapp@nasdaqomx.com

Feed Information:

Fiber Line (Encompass Media): 4463

Can also be found on Satellite:

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC ¾

SR 13.235

DR 18.295411

MOD 4:2:0

DVBS QPSK

If you have any questions, please contact Jen Knapp at (212) 401-8916.

Facebook and Twitter:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page at:

http://www.facebook.com/nasdaqomx               

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx

Webcast:

A live webcast of the NASDAQ Closing Bell will be available at:

http://www.nasdaq.com/about/marketsitetowervideo.asx or http://social.nasdaqomx.com.

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.                             

About Amarin Corporation PLC (AMRN):

Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (icosapent ethyl). Amarin reported positive, statistically significant top-line results for both of its two pivotal Phase 3 clinical trials, the MARINE trial (investigation of AMR101 as a treatment for patients with very high triglycerides [>500 mg/dL]), as reported in November 2010, and the ANCHOR trial (investigation of AMR101 for the treatment of patients on statin therapy with high triglycerides [>200 and

About NASDAQ OMX:

The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with more than 3,500 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX first North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook (http://www.facebook.com/pages/NASDAQ-OMX/108167527653) and Twitter (http://www.twitter.com/nasdaqomx). 

NDAQA

In This Story

NDAQ